GAM
KRYS icon

Gotham Asset Management’s Krystal Biotech KRYS Stock Holding History

Gotham Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$342K Buy
1,323
+20
+2% +$5.32K ﹤0.01% 1579
2025
Q4 		$321K Sell
1,303
-4
-0.3% -$842 ﹤0.01% 1552
2025
Q3 		$231K Buy
+1,307
New +$196K ﹤0.01% 1580
2025
Q2 		– Sell
-4,804
Closed -$866K – 1707
2025
Q1 		$866K Buy
+4,804
New +$808K 0.01% 1049

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gotham Asset Management's KRYS Position: Q1 2026 in Review

Gotham Asset Management increased its Krystal Biotech (KRYS) stake by 1.5% in Q1 2026, buying an estimated $5.32K and bringing the position to 1,323 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Gotham Asset Management first reported a position in KRYS in Q1 2025 and has held it in 4 quarters since. The position peaked at $866K in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Gotham Asset Management held 1,323 shares of Krystal Biotech worth $342K as of Q1 2026.
  • Gotham Asset Management bought 20 Krystal Biotech shares in Q1 2026, an estimated $5.32K.
  • Krystal Biotech made up ﹤0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1579 holding.
  • Gotham Asset Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 4 quarters since.
  • Gotham Asset Management's Krystal Biotech position peaked at $866K in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.